Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

Open access
Touchberry, Chad D., Green, Troy M., Tchikrizov, Vladimir, Mannix, Jaimee E., Mao, Tiffany F., Carney, Brandon W., Girgis, Magdy, Vincent, Robert J., Wetmore, Lori A., Dawn, Buddhadeb, Bonewald, Lynda F., Stubbs, Jason R., Wacker, Michael J. · 2013 · American Journal of Physiology-Endocrinology and Metabolism

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone released primarily by osteocytes that regulates phosphate and vitamin D metabolism. Recent observational studies in humans suggest that circulating FGF23 is independently associated with cardiac hypertrophy and increased mortality, but it is unknown whether FGF23 can directly alter cardiac function. We found that FGF23 significantly increased cardiomyocyte cell size in vitro, the expression of gene markers of cardiac hypertrophy, and total protein content of cardiac muscle. In addition, FGFR1 and FGFR3 mRNA were the most abundantly expressed FGF receptors in cardiomyocytes, and the coreceptor α-klotho was expressed at very low levels. We tested an animal model of chronic kidney disease ( Col4a3−/−mice) that has elevated serum FGF23. We found elevations in common hypertrophy gene markers in Col4a3−/−hearts compared with wild type but did not observe changes in wall thickness or cell size by week 10. However, the Col4a3−/−hearts did show reduced fractional shortening (−17%) and ejection fraction (−11%). Acute exposure of primary cardiomyocytes to FGF23 resulted in elevated intracellular Ca 2+([Ca 2+]i; F/F o+ 86%) which was blocked by verapamil pretreatment. FGF23 also increased ventricular muscle strip contractility (67%), which was inhibited by FGF receptor antagonism. We hypothesize that although FGF23 can acutely increase [Ca 2+]i, chronically this may lead to decreases in contractile function or stimulate cardiac hypertrophy, as observed with other stress hormones. In conclusion, FGF23 is a novel bone/heart endocrine factor and may be an important mediator of cardiac Ca 2+regulation and contractile function during chronic kidney disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1152/ajpendo.00596.2012

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 195

Metadata

Authors
Touchberry, C. D., Green, T. M., Tchikrizov, V., Mannix, J. E., Mao, T. F., Carney, B. W., Girgis, M., Vincent, R. J., Wetmore, L. A., Dawn, B., Bonewald, L. F., Stubbs, J. R., & Wacker, M. J.
Venue
American Journal of Physiology-Endocrinology and Metabolism
Published
2013-04-15
Volume
304
Issue
8
Pages
E863-E873
ISSN
  • 0193-1849 (ISSN-L)
  • 1522-1555
OpenAlex
W2152330606
Cited by
195
References
7
FWCI
13.92
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. https://app.cochat.ai/papers/10.1152/ajpendo.00596.2012
The paper
Touchberry, C. D., Green, T. M., Tchikrizov, V., Mannix, J. E., Mao, T. F., Carney, B. W., Girgis, M., Vincent, R. J., Wetmore, L. A., Dawn, B., Bonewald, L. F., Stubbs, J. R., & Wacker, M. J. (2013). FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. American Journal of Physiology-Endocrinology and Metabolism. https://doi.org/10.1152/ajpendo.00596.2012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.